Showing posts sorted by date for query BACTERIOPHAGE. Sort by relevance Show all posts
Showing posts sorted by date for query BACTERIOPHAGE. Sort by relevance Show all posts

Tuesday, October 29, 2024


First World War superbug treatment could save NHS millions – but is blocked by red tape

Joe Pinkstone
Tue 29 October 2024\
THE TELEGRAPH

The use of bacteria-killing viruses known as phages to treat patients dates back to the First World War


William Stocking, 81, has spent much of the last four years in and out of hospital as an infection slowly destroys his leg.

He caught a superbug, an antimicrobial-resistant strain of Staphylococcus aureus, after going to the Royal Devon and Exeter Hospital in early 2020 with a chest infection.

Superbugs are notorious for being hard to treat because of their immunity to antibiotics. Around 52,000 people a year catch superbugs in the UK, causing around 2,000 deaths and costing the NHS around £180 million annually.

However, a little-known treatment dating back to the First World War is available, if NHS doctors are prepared to spend hundreds of hours fighting a mountain of government red tape.

Bacteriophages, known as phages, are bacteria-killing viruses that inject their own DNA into a bacteria to seize control of the cell and produce more phages until the bacteria bursts.

It is an effective killing mechanism and phages are the most abundant entity in the world.

They are highly precise with only specific strains of bacteria targeted by a certain phage, and phages can be effective against superbug infections impervious to all known medication.

Doctors are increasingly looking at phage therapy to help patients who are otherwise out of options, and Mr Stocking is a pioneering patient in the UK.

The superbug bacteria was attracted to the metal in his knee replacement which he had in the late 1980s following a career-ending injury suffered in the line of duty while a sergeant in the Hampshire Constabulary.

William Stocking and his wife Lorraine hope the treatment will allow him to walk properly again - Eddie Mulholland

“It works a bit like [the video game] Pac-Man and goes around eating the infection. It’s been a partial success so far, and time will tell,” Mr Stocking told The Telegraph from his hospital bed at the Royal National Orthopaedic Hospital (RNOH) in north-west London after receiving his third and final dose of phage therapy last week.

“I’ve had numerous pills, potions, antibiotics, transfusions and none of them worked. We have exhausted the available options and are down to phage which was raised as a last resort,” Mr Stocking said.

The cost of this bespoke and unique treatment, which was paid for and administered by the NHS, is thought to be similar to a course of the most premium and highly-preserved antibiotics, at a few thousand pounds. The procedure is a last hope for him and his wife, Lorraine, 72, also a retired police officer.

After retiring, the couple moved to a smallholding in Devon and ran a rural B&B for a decade. On Wednesday, they celebrated their 48th wedding anniversary by sharing a Mars bar in hospital.

Mr Stocking now has three sinuses on his left leg from his infection which weep constantly and need regular tending.

“It’s got more and more painful, and it’s got worse and worse to the point where I can’t walk very far and I am very unstable,” Mr Stocking said.

“It has prevented us doing lots of things we would have wanted to have done. Everything has just been put on hold,” adds Lorraine.



The couple were not put off by the therapy’s experimental nature, and hope it could allow Mr Stocking’s leg to heal enough to allow him to walk with greater ease.

“I thought it was brilliant when it was first suggested to me,” Mr Stocking said.

“It was put to me that I would be the first one to have phage for something like this and that it was an experiment that could work for a lot of people and, if it works, also help a lot of people.

“I am 81 and I can’t pioneer much more with my life so whatever I can do to be of use to anybody then let’s give it a go.

“I’m never going to win a Butlins Knobbly Knees competition, but I’d like to see my leg sufficiently well to use it and walk. Walking is the main thing, to get about for the final few years of my life.”

But the path to this point, the couple say, has been exhausting. Endless red tape has delayed treatment and made access to phage a multi-year struggle.


Phage therapy is not a licensed medicine in the UK and a phage from the UK can not be provided to an NHS patient unless it reaches Good Manufacturing Practice (GMP) standard. There is no GMP facility for phages in the UK.

However, a “GMP-like” phage from abroad can be used for compassionate use if it is approved by the Medicines and Health Products Regulatory Agency (MHRA) and imported.

Proving this, and sourcing an importer to bring an unlicensed, non-GMP medicine from a laboratory in Brussels required more than 200 hours of work from Mr Stocking’s clinical team and caused most of the delays.
‘Get on with it’

The Stocking family and the doctors both urged politicians and regulators to alter the current legislation to make it easier for other patients to access phage therapy through the NHS.

“While all the faceless bureaucracy goes on we are left 200 miles away with no answers,” said Mr Stocking.

“It’s not been a very pleasant time. Phage could be useful to a lot of people but red tape is holding it all up. It has been months and months of hanging around.

“Give it a chance, expedite it,” he urged politicians. “Money is money but lives are lives and limbs are limbs. Get on with it.”


A medic treats Mr Stocking - RNOH Images

Lorraine said phage therapy could save the NHS millions of pounds a year and help treat thousands of different people around the country who have run out of options.

“Behind the delays and red tape are mental, emotional and physical impacts,” she said.

“His condition three-and-a-half years ago was not so bad and maybe phage would be more effective had we not been this far down the line before getting it.”

Tariq Azamgarhi, the principal antimicrobial pharmacist at RNOH, and Dr Antonia Scobie, research lead for the Bone Infection Unit at RNOH, were central in securing phage therapy for Mr Stocking.

Mr Azamgarhi said phages “fall between the cracks” of much of the existing UK regulation, and urged politicians to make changes to help doctors better access phages for compassionate use in patients with no other option.
‘Huge potential’

Dr Scobie, who is also lead for the UK Clinical Working Group for bacteriophage therapy, told The Telegraph: “We are in the camp of strongly supporting phage therapy and I think it has a huge amount of potential.

“We’re under no illusion that on its own, phage therapy is never going to be able to replace antibiotics but what it does offer is a safe treatment that can be an adjunct to our existing therapies.

“We would never dream of injecting the phage and just crossing fingers and hoping that would be enough. It needs to be used in the right way, but it’s an extra tool. I think it has huge potential and it just needs to be used in the right way.”

The RNOH team is now beginning the long-winded process again for three other superbug patients with joint infections and is helping other hospitals around the country tackle the paperwork.

“We hope that by opening various doors in the process that it may be easier for them and help the next patient,” Dr Scobie said.

A report by MPs on the science and technology committee said earlier this year that the MHRA should change its rules to allow for compassionate use in last-resort medical cases, like those of Mr Stocking.

They also urged the agency to set out new guidance for how doctors can use non-GMP phages.

The MHRA has missed some deadlines set out by the committee at the start of the year and is currently reviewing proposed guidance. It says this will be published “in due course”.

The MHRA declined to comment.

Wednesday, October 09, 2024

 

Viruses are teeming on your toothbrush, showerhead



New study finds ‘untapped biodiversity’ in the bathroom



Northwestern University

Showered 

image: 

In a new study, samples collected from showerheads and toothbrushed comprised more than 600 different viruses — and no two samples were alike.

view more 

Credit: Ivan Radic





Step aside tropical rainforests and coral reefs — the latest hotspot to offer awe-inspiring biodiversity lies no further than your bathroom.

In a new Northwestern University-led study, microbiologists found that showerheads and toothbrushes are teeming with an extremely diverse collection of viruses — most of which have never been seen before.

Although this might sound ominous, the good news is these viruses don’t target people. They target bacteria.

The microorganisms collected in the study are bacteriophage, or “phage,” a type of virus that infects and replicates inside of bacteria. Although researchers know little about them, phage recently have garnered attention for their potential use in treating antibiotic-resistant bacterial infections. And the previously unknown viruses lurking in our bathrooms could become a treasure trove of materials for exploring those applications.

The study will be published Wednesday (Oct. 9) in the journal Frontiers in Microbiomes.

“The number of viruses that we found is absolutely wild,” said Northwestern’s Erica M. Hartmann, who led the study. “We found many viruses that we know very little about and many others that we have never seen before. It’s amazing how much untapped biodiversity is all around us. And you don’t even have to go far to find it; it’s right under our noses.”

An indoor microbiologist, Hartmann is an associate professor of civil and environmental engineering at Northwestern’s McCormick School of Engineering and a member of the Center for Synthetic Biology.

The return of ‘Operation Pottymouth’

The new study is an offshoot of previous research, in which Hartmann and her colleagues at University of Colorado at Boulder characterized bacteria living on toothbrushes and showerheads. For the previous studies, the researchers asked people to submit used toothbrushes and swabs with samples collected from their showerheads.

Inspired by concerns that a flushing toilet might generate a cloud of aerosol particles, Hartmann affectionately called the toothbrush study, “Operation Pottymouth.”

“This project started as a curiosity,” Hartmann said. “We wanted to know what microbes are living in our homes. If you think about indoor environments, surfaces like tables and walls are really difficult for microbes to live on. Microbes prefer environments with water. And where is there water? Inside our showerheads and on our toothbrushes.”

Diversity and opportunities

After characterizing bacteria, Hartmann then used DNA sequencing to examine the viruses living on those same samples. She was immediately blown away. Altogether, the samples comprised more than 600 different viruses — and no two samples were alike.

“We saw basically no overlap in virus types between showerheads and toothbrushes,” Hartmann said. “We also saw very little overlap between any two samples at all. Each showerhead and each toothbrush is like its own little island. It just underscores the incredible diversity of viruses out there.”

While they found few patterns among all the samples, Hartmann and her team did notice more mycobacteriophage than other types of phage. Mycobacteriophage infect mycobacteria, a pathogenic species that causes diseases like leprosy, tuberculosis and chronic lung infections. Hartmann imagines that, someday, researchers could harness mycobacteriophage to treat these infections and others.

“We could envision taking these mycobacteriophage and using them as a way to clean pathogens out of your plumbing system,” she said. “We want to look at all the functions these viruses might have and figure out how we can use them.”

Most microbes ‘will not make us sick’

But, in the meantime, Hartmann cautions people not to fret about the invisible wildlife living within our bathrooms. Instead of grabbing for bleach, people can soak their showerheads in vinegar to remove calcium buildup or simply wash them with plain soap and water. And people should regularly replace toothbrush heads, Hartmann says. Hartmann also is not a fan of antimicrobial toothbrushes, which she said can lead to antibiotic-resistant bugs.

“Microbes are everywhere, and the vast majority of them will not make us sick,” she said. “The more you attack them with disinfectants, the more they are likely to develop resistance or become more difficult to treat. We should all just embrace them.”

The study, “Phage communities in household-related biofilms correlate with bacterial hosts but do not associate with other environmental factors,” was supported by Northwestern University.

Monday, October 07, 2024

 OUR FRIEND THE BACTERIOPHAGE

Bacteria-fighting viruses team up to treat drug-resistant superbugs



UChicago Pritzker School of Molecular Engineering researchers screened a library of bacteriophages to find combinations of the viruses that can work together to fight antibiotic-resistant Klebsiella pneumoniae infections



University of Chicago

UChicago Pritzker School of Molecular Engineering Asst. Prof. Mark Mimee and research specialist Ella Rotman 

image: 

Researchers at the University of Chicago Pritzker School of Molecular Engineering (PME) and UChicago Medicine, including Asst. Prof. Mark Mimee (left) and research specialist Ella Rotman, have shown that a mixture of collections of bacteriophages can successfully treat antibiotic-resistant infections in mice.

view more 

Credit: UChicago Pritzker School of Molecular Engineering / Jason Smit




Researchers have a new battle tactic to fight drug-resistant bacterial infections. Their strategy involves using collections of bacteriophages, viruses that naturally attack bacteria. In a new study, researchers at the University of Chicago Pritzker School of Molecular Engineering (PME) and UChicago Medicine have shown that a mixture of these phages can successfully treat antibiotic-resistant Klebsiella pneumoniae infections in mice.

At the same time, however, the team’s work revealed just how complex the interactions between phages and bacteria can be; the viruses predicted to be most effective in isolated culture dishes did not always work in animals. Moreover, both phages and bacteria can evolve over time – in some cases, phages evolved to be more efficient in killing bacteria while in other cases, Klebsiella evolved resistance to the phages.

“We still think phages are an incredibly promising approach to treating drug-resistant bacteria such as Klebsiella,” said Mark Mimee, assistant professor of molecular engineering and senior author of the new work, published in Cell Host & Microbe. “But phages are like a living, constantly changing antibiotic which gives them a lot of complexity.”

Klebsiella pneumoniae are common bacteria found in people’s intestines where they cause little harm. However, when the bacteria escape to other body sites, such as open wounds, the lungs, the bloodstream, or the urinary tract, they can cause more severe infections. K. pneumoniae are often spread within hospital settings, and drug-resistant strains have become common.

“In my clinic, I see patients with recurrent urinary tract infections caused by Klebsiella,” says urogynecologist Sandra Valaitis, MD, of UChicago Medicine, a co-author of the new work. “Often these bacterial strains develop resistance to oral antibiotics, leaving patients with fewer options to clear the infection. We urgently need new ways of treating these bacteria.”

Phages, for more than a century, have been known as a natural enemy of bacteria and studied for their potential to treat infections. However, phages are usually very specific for one type of bacteria and predicting these matches has been difficult.

In the new research, Ella Rotman – a scientist in the Mimee Lab – screened wastewater to isolate phages that could effectively kill 27 different Klebsiella strains, including 14 that were newly isolated from University of Chicago patients. The team identified several dozen phages with the capability of killing at least some Klebsiella strains, Then, the researchers analyzed what genetic factors in the bacteria made them most prone to being killed or weakened by each of those phages.

Based on that analysis, Rotman and her colleagues developed a mixture of five phages that each targeted different components of the bacteria. In culture dishes as well as mice, this phage cocktail made antibiotic-resistant Klebsiella bacteria more likely to be attacked by the immune system and, in some cases, more susceptible to treatment with antibiotics. However, in other cases, the bacteria became more antibiotic resistant after treatment.

“It’s one of those things where biology often doesn’t work the way you want it to,” says Mimee. “But it gives us an opportunity to study the detailed dynamics between the phages and the bacteria.”

By exposing the phage mixture to a series of isolated Klebsiella bacteria, the researchers gave the phage the opportunity to evolve. This improved the ability of the cocktail to kill Klebsiella. In mice, the mixture effectively killed or weakened Klebsiella. The researchers observed co-evolution between the bacteria and phage in the mouse intestines, where the Klebsiella evolved to evade phage attack and the phage countered to better infect the altered bacteria.

Mimee’s lab group is continuing experiments to better understand how different phage and bacteria pairs interact with each other and how the presence of other phages and bacteria – naturally found in the human body—influences that. At the same time, in collaboration with Valaitis, they are seeking approval from the Food and Drug Administration (FDA) for a small clinical trial testing the phage mixture in patients with urinary tract infections.

“This research is a positive step forward in trying to sort out the complexities of phages and move them closer to the clinic,” says Mimee.

Citation: “Rapid design of bacteriophage cocktails to suppress the burden and virulence of gutresident carbapenem-resistant Klebsiella pneumoniae,” Rotman et al, Cell Host & Microbe, October 4, 2024. DOI: https://doi.org/10.1016/j.chom.2024.09.004

Funding: National Science Foundation, National Institutes of Health, Arnold and Mabel Beckman Foundation, BRaVE Phage Foundry at Lawrence Berkeley National Laboratory.

Monday, September 09, 2024

 

HKUST engineering researchers discover an effective and environment-friendly disinfectan




Hong Kong University of Science and Technology
Schematic illustration of screening halogenated phenolic DBPs for potential disinfectants 

image: 

Schematic illustration of screening halogenated phenolic DBPs for potential disinfectants based on their structural properties and photodegradation kinetics.

view more 

Credit: HKUST

\



A widely used disinfectant worldwide, chloroxylenol, has been associated with eco-toxicological threats in water environments due to its relatively high chemical stability and massive consumption. Researchers at the School of Engineering of the Hong Kong University of Science and Technology (HKUST) have discovered a promising alternative known as 2,6-dichlorobenzoquinone (2,6-DCQ), which works more effectively in combating certain common bacteria, fungi and viruses, and can be rapidly degraded and detoxified in receiving waters.

This groundbreaking study is led by Prof. ZHANG Xiangru from HKUST's Department of Civil and Environmental Engineering, who has been studying disinfection byproducts (DBPs) for many years. During the pandemic outbreak, Prof. Zhang noticed that chloroxylenol is structurally similar to some halo-phenolic DBPs previously discovered by his team, which have been shown to rapidly degrade by solar photolysis.

Inspired by the structural property and degradability of some halo-phenolic DBPs, the research team managed to select an effective broad-spectrum disinfectant from the DBPs that can be rapidly degraded and detoxified in receiving waters. The research team tested the efficacy of 10 different DBPs in inactivating various pathogens, including E. coli (a type of bacteria associated with colorectal cancer), Staphylococcus aureus (bacteria), Candida albicans (fungi), and bacteriophage MS2 (viruses). They found that 2,6-DCQ was 9 to 22 times more effective than chloroxylenol in inactivating these bacteria, fungi, and viruses.

Furthermore, they found that the developmental toxicity of 2,6-DCQ to marine polychaete embryos decreased quickly due to its rapid degradation via hydrolysis in receiving seawater, even in the absence of sunlight. Two days after being discharged into seawater, 2,6-DCQ exhibited 31 times lower developmental toxicity compared to chloroxylenol.

“We discovered that the selected DBP exhibited substantially stronger antimicrobial efficacy than chloroxylenol and that its concentration and associated developmental toxicity in receiving seawater decreased rapidly, even in darkness,” Prof. Zhang said.

He emphasized the pressing need for more effective and eco-friendly disinfectants, particularly in the wake of the COVID-19 pandemic. “Chloroxylenol has been frequently detected in aquatic environments; for instance, its concentration has reached up to 10.6 μg/L in river water in Hong Kong. Toxicological studies have reported adverse effects of chloroxylenol on aquatic organisms, including endocrine disruption, embryonic mortality, and malformations. Chronic exposure to chloroxylenol at environmental concentrations (~4.2 μg/L) can cause gene regulation and morphological changes in rainbow trout.”

The team's discovery of 2,6-DCQ as a promising alternative is an important step towards addressing this global need. The results suggest that 2,6-DCQ may be used as a disinfectant on a wide range of occasions, including personal care products (such as hand cleansers, detergent, and soap), paint, textiles, metal working fluids, medical scrubs, as well as sanitation for households, food processing equipment, surgical instruments, and public places.

“This innovative study not only provides a potential solution to better support human biosecurity while prioritizing environmental sustainability, but also carries significant implications for the development of green disinfectants and other green industrial products by exploiting the slightly alkaline nature of seawater. For example, scientists may design and develop other industrial products such as pesticides, pharmaceuticals, and personal care products that can be rapidly degraded by hydrolysis in receiving seawater,” Prof. Zhang elaborated.

Their findings have been published in the first-rate multidisciplinary journal Nature Communications. The research team included Dr. HAN Jiarui, currently a Research Assistant Professor at HKUST, and Dr. LI Wanxin, currently an Assistant Professor at Xi'an Jiaotong-Liverpool University. They are both PhD graduates from HKUST's Department of Civil and Environmental Engineering and were postdoctoral fellows in Prof. Zhang’s group during the study. 

Looking ahead, Prof. Zhang plans to explore the relationships between disinfection efficiency and degradability of halophenols with their molecular fingerprints through machine learning. He hopes future investigations will shed light on the further development of optimal disinfectants.
 

Sunday, June 02, 2024

 

Nanoparticle vaccines: A leap forward in veterinary medicine



HUAZHONG AGRICULTURAL UNIVERSITY
Adaptive immune activation induced by NP (SAPN/VLPS) vaccines. 

IMAGE: 

ADAPTIVE IMMUNE ACTIVATION INDUCED BY NP (SAPN/VLPS) VACCINES.

view more 

CREDIT: ANIMAL DISEASES





A recent review explores the innovative use of self-assembled protein nanoparticles (SAPNs) and virus-like particles (VLPs) in veterinary vaccine development. The research highlights the superior safety and efficacy of these nanovaccines over traditional formulations, offering a promising future for animal health and disease prevention.

Classical vaccines often rely on traditional technologies, such as live attenuated or inactivated pathogens, which carry inherent risks including reduced immunogenicity under certain conditions and potential safety concerns. This has spurred the need for innovative approaches that can provide safer and more effective prophylactic solutions in veterinary medicine. SAPNs emerge as a cutting-edge solution, harnessing the power of nanotechnology to revolutionize vaccine design and implementation.

The article (DOI: 10.1186/s44149-024-00119-w), published on 10 May 2024, in the Animal Diseases journal, researchers at Zhejiang University's Institute of Preventive Veterinary Medicine, delve into the development and application of SAPNs and VLPs, offering a detailed discussion of their potential in veterinary medicine.

The article focuses on various types of SAPNs, including natural and synthetically designed nanoparticles. These nanoparticles are tailored to enhance the immune system's ability to recognize and respond to pathogens more effectively. Key highlights include the use of animal virus-derived nanoparticles and bacteriophage-derived nanoparticles, which have shown the potential to elicit strong cellular and humoral responses. The nanoparticles' ability to mimic pathogen structures enables them to trigger a more substantial immune reaction, potentially leading to long-lasting immunity. Researchers have documented successes in using these nanoparticles to protect against diseases like foot-and-mouth disease and swine fever, showcasing their broad applicability and effectiveness.

Dr.Fang He, a principal investigator of the article, expressed the significance of this review, " Nanoparticle vaccines have demonstrated enormous promise and should be considered promising techniques in veterinary vaccine development."

Veterinary nanoparticle vaccines have broad implications, with the potential to extend the benefits beyond veterinary applications into human health. The enhanced safety and immunogenicity of these vaccines could lead to the development of advanced vaccines for human use. Additionally, by reducing the environmental impact of livestock diseases, this technology may contribute to more sustainable agricultural practices globally.

###

References

DOI

10.1186/s44149-024-00119-w

Original Source URL

https://doi.org/10.1186/s44149-024-00119-w

About Animal Diseases

Animal Diseases(ISSN 2731-0442, CN 42-1946/S)is a peer-reviewed, free open access academic journal sponsored by Huazhong Agricultural University. The journal promotes the One Health initiative and is committed to publishing high-quality innovated and prospective works in animal disease research/application that are closely related to human health. The founding chief editors are Drs. Huanchun Chen (Huazhong Agricultural University, China) and Zhen F. Fu (University of Georgia, USA). It has been indexed by ESCI in 2024.

  

Personalized phage therapy heals resistant wounds-squeaks makes full recovery




THE HEBREW UNIVERSITY OF JERUSALEM
Squeaks 

IMAGE: 

RELAXING AFTER FULL RECOVERY

view more 

CREDIT: MILAT AND LARRY BERKLEY



A new study demonstrates an advance in treating antibiotic-resistant infections in animals through personalized phage therapy. The treatment combined a specific anti-P. aeruginosa phage applied topically with ceftazidime administered intramuscularly, resulting in the complete healing of a persistent surgical wound after fourteen weeks. This highlights the potential of phage therapy as a practical and effective solution for antibiotic-resistant infections in veterinary practice, with implications for human medicine as well.

 

Link to pictures: https://drive.google.com/drive/folders/12ntfvgd_ZdpEYtMsgkZRjS9vB89ps5XM?usp=sharing

A new study led by Prof. Ronen Hazan and his team, from the Faculty of Dental Medicine at the Hebrew University of Jerusalem, in collaboration with the team of Vet Holim, JVMV -Veterinary medical center in Kiryat -Anavim, Israel, has shown an advance in the treatment of antibiotic-resistant infections in animals. This research, focusing on a five-year-old Siamese cat Squeaks  with a multidrug-resistant Pseudomonas aeruginosa infection post-arthrodesis surgery, marks the first published documented application of personalized phage therapy in veterinary medicine.

Squeaks, initially treated at the JVMV for injuries sustained from a high-rise fall, developed a severe infection in the right hind leg following multiple surgeries. This infection persisted despite various antibiotic treatments over four months. Facing a potential implant-replacement surgery, the team turned to the new treatment which involved a meticulously designed combination of a specific anti-P. aeruginosa phage, a virus that kills bacteria, applied topically to the surgical wound and ceftazidime administered intramuscularly. Moreover, the owners of the cat, after short demonstration, provides most of the treatment doses of phages and antibiotics at their home.

The integration of phage therapy with antibiotics was aimed at targeting the pathogen effectively and directly at the site of infection, leveraging the phage’s ability to be applied topically, which simplifies administration and maximizes its concentration at the infection site. This approach allowed the surgical wound, which had remained open for five months, to fully heal after to fourteen weeks of treatment.

The successful outcome of this case underscores the critical need for novel therapeutics like phage therapy to address the growing concern of antibiotic-resistant infections, which affect up to 8.5% of surgical sites following orthopedic surgeries in companion animals. These infections not only pose significant health risks to the animals but also increase the morbidity, mortality, and costs associated with these procedures.

Recent studies suggest that phage therapy, already showing high success rates in human medicine for treating orthopedic infections and chronically infected wounds, can offer a promising solution for similar issues in veterinary practice. Moreover, the successful treatment of this cat by its owners at home highlights the practicality and efficacy of personalized phage therapy, which could be extended to treat other pets facing similar antimicrobial resistance challenges.

Interestingly, opposite to common situations, this case was performed on an animal based on the team's insights from treating humans first.

The positive reception from veterinarians and pet owners regarding phage therapy points to a growing awareness and acceptance of this treatment option. As the new treatment continues to be explored in veterinary settings, it not only improves the health and well-being of pets but also offers valuable data that contribute to the broader application of phage therapy in both animals and humans. This bridging of data can enhance treatment protocols and outcomes across a variety of bacterial infections, potentially changing the landscape of infection treatment in both veterinary and human medicine.

Phage therapy: In-depth discussion on ethical considerations and regulatory landscape at upcoming European conference “Targeting Phage Therapy 2024”





MITOCHONDRIA-MICROBIOTA TASK FORCE

Ms. Barbara Brenner, speaker at Targeting Phage Therapy 2024 

IMAGE: 

BARBARA BRENNER, A LEGAL EXPERT IN MEDICAL LAW AND HUMAN RIGHTS, WILL DELIVER A TALK TITLED "REGULATORY RESTRICTIONS VS. HUMAN RIGHTS, THE HIPPOCRATIC OATH, AND THE FREEDOM OF THERAPY – THE LEGAL ASPECT OF PHAGE THERAPY" AT TARGETING PHAGE THERAPY ON JUNE 20-21, 2024

view more 

CREDIT: TARGETING PHAGE THERAPY




The 7th World Conference on Targeting Phage Therapy 2024 is set to take place on June 20-21 at the Corinthia Palace in Malta, welcoming over 150 attendees from 30 countries and featuring more than 32 communications. This annual event showcases the latest advancements in phage research and therapy, emphasizing how these developments could revolutionize healthcare practices globally.

The Ethical Considerations and Regulatory Landscape of Phage Therapy will be highlighted

Targeting Phage Therapy 2024 will include a dedicated session on the ethical and regulatory aspects of phage therapy, particularly in Europe. Barbara Brenner, a legal expert in medical law and human rights, will deliver a talk titled "Regulatory Restrictions vs. Human Rights, the Hippocratic Oath, and the Freedom of Therapy – The Legal Aspect of Phage Therapy". Her presentation will focus on balancing regulatory frameworks with the urgent need for accessible, life-saving treatments.

Phage therapy faces significant regulatory and ethical challenges, and Brenner will address several critical points:

- Regulatory Frameworks and Human Rights: Brenner will provide an overview of EU and German legal and regulatory frameworks, highlighting the tension between the right to safe drugs and the right to life-saving treatment in emergencies, especially concerning antimicrobial-resistant (AMR) infections and non-GMP phages.

- Ethical and Legal Questions: The session will explore whether it is ethical to deny life-saving treatments for safety reasons and whether regulatory bodies like the FDA and EMA can be held liable for prohibiting non-GMP phages if GMP phages are unavailable or unaffordable. Additionally, Brenner will discuss the validity of scientific evidence derived from anecdotal sources versus the necessity of randomized controlled trials (RCTs) and whether these trials need to be redesigned. The legal status of phage therapy as "experimental" and the potential liability of clinicians who refuse phage therapy when it could save a patient will also be examined.

- Combatting Antimicrobial Resistance (AMR): The presentation will include the One Health approach, integrating human, animal, and environmental health practices. Brenner will highlight Georgia's successful model, advocating for the promotion of phages as primary interventions, reserving chemical antibiotics for situations where phages are ineffective.

 

Speakers Lineup

  • Robert T. Schooley, University of California, San Diego, USA

Clinical Trials in Phage Therapeutics: Looking Under the Hood

  • Ekaterina Chernevskaya, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Russia

Adaptive Phage Therapy in the Intensive Care Unit: From Science to Patients

  • Jean-Paul Pirnay, Queen Astrid Military Hospital, Belgium

Magistral Phage Preparations: Is This the Model for Everyone?

  • Barbara Brenner, Kanzlei BRENNER, Germany

Regulatory restrictions vs. Human Rights, the Hippocratic oath and the Freedom of therapy– The legal aspect of phage therapy

  • Nannan Wu, Shanghai Public Health Clinical Center, Fudan University, China

Phage Therapy: A Glimpse into Clinical Studies Involving Over 150 Cases

  • Graham F. Hatfull, University of Pittsburgh, USA

Mycobacteriophages and Their Therapeutic Potential

  • Antonia P. Sagona, University of Warwick, United Kingdom

Genetic Engineering of Phages to Target Intracellular Bloodstream E.coli Infections

  • Paul Turner, Yale University, USA

Leveraging Evolutionary Trade-Offs in Development of Phage Therapy

  • Pieter-Jan Ceyssens, Sciensano, Belgium

Quality control of phage Active Pharmaceutical Ingredients (APIs) in Belgium

  • Wolfgang Weninger, Medical University of Vienna, Austria

The Phageome in Normal and Inflamed Human Skin

  • Sabrina Green, KU Leuven, Belgium

Making Antibiotics Great Again: Phage resistance in vivo correlates to resensitivity to antibiotics in pan-resistant Pseudomonas aeruginosa

  • Rodrigo Ibarra Chávez, University of Copenhagen, Denmark

Phage Satellites, a Diversity of Extradimensional Symbionts and Pathways to Phage Therapy

  • Domenico Frezza, University of Roma Tor Vergata, Italy

Towards efficient phage therapies: investigation of phage / bacteria equilibrium with metagenome of dark matter in natural samples

  • Besarion Lasareishvili, Eliava Institute of Bacteriophage, Microbiology and Virology, Georgia

Modern Concepts of Phage Therapy: An Immunologist’s Vision

  • Kilian Vogele, Invitris, Germany

Cell-Free Production of Personalized Therapeutic Phages Targeting Multidrug-Resistant Bacteria

  • Frederic Bertels, Max Planck Institute for Evolutionary Biology, Germany

Improving Phages through Experimental Evolution

  • Eugene V Koonin, National Institutes of Health, USA

Evolution and megataxonomy of viruses: the place of phages in the virosphere

  • Federica Briani, University of Milan, Italy

Addressing Phage Resistance to Enhance the Robustness of Phage Therapy for Pseudomonas aeruginosa Infections in People with Cystic Fibrosis

  • Jumpei Fujiki, University of California San Diego, USA

Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver disease

 

Targeting Phage Therapy 2024 Supporters: Cellexus, Precision Phage, Jafral.

Contributing Partner: PHAGE Therapy, Applications, and Research Journal.

Media Partner: Bacteriophage.news.

For more information, registration details, list of attendees and the program, please visit: www.phagetherapy-site.com.


SEE

https://plawiuk.blogspot.com/search?q=PHAGES